In 2012, Hauschild et al. demonstrated a 70% reduction in the risk of death (HR = 0.30) in BRAF p.V600E-mutated metastatic melanoma patients treated with dabrafenib, compared to chemotherapy (dacarbazine) control [29]. This evidence concerns the gene BRAF and metastatic melanoma.